Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Elisabeth Souhami"'
Publikováno v:
Journal of Clinical & Translational Endocrinology, Vol 1, Iss 2, Pp 31-37 (2014)
Objective: To compare the efficacy and safety of the once-daily prandial glucagon-like peptide-1 receptor agonist lixisenatide with the dipeptidyl peptidase-4 inhibitor sitagliptin in patients aged
Externí odkaz:
https://doaj.org/article/74aa8d68fbc84b3cae3cc7f257f99b95
Autor:
Rory J. McCrimmon, Philip Home, Alice Cheng, Francesco Giorgino, Vivian Fonseca, Elisabeth Souhami, Agustina Alvarez, Pascaline Picard, Julio Rosenstock
Publikováno v:
Diabetes, Obesity and Metabolism. 24:2391-2399
To explore details of the incidence and rates of daytime and nocturnal hypoglycaemia, levels of hypoglycaemia, and relationship to glycated haemoglobin (HbA1c), when comparing iGlarLixi versus premixed biphasic insulin aspart 30 (BIAsp 30) in the Sol
Autor:
Xiaohui Guo, Wenying Yang, Junqing Zhang, Xiaolin Dong, Ming Liu, Shenghong Gu, Felipe Lauand, Lingyu Li, Qiong Huang, Lei Kang, Elisabeth Souhami
Publikováno v:
Diabetes, Obesity and Metabolism.
Autor:
Francesco Giorgino, Julio Rosenstock, Robert Ritzel, Oğuzhan Deyneli, Agustina Alvarez, Elisabeth Souhami, Lydie Melas-Melt, Rory J. McCrimmon
Publikováno v:
Diabetologie und Stoffwechsel.
Autor:
null Xiaohui Guo, null Wenying Yang, null Junqing Zhang, null Xiaolin Dong, null Ming Liu, null Shenghong Gu, null Felipe Lauand, null Lingyu Li, null Qiong Huang, null Lei Kang, null Elisabeth Souhami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96f477950deb6dc6d6d465405c2616cf
https://doi.org/10.1111/dom.15074/v2/response1
https://doi.org/10.1111/dom.15074/v2/response1
Autor:
Karen Palmer, Elisabeth Souhami, Julio Rosenstock, Elisabeth Niemoeller, Chen Ji, David Russell-Jones, Melanie J. Davies, Neil Skolnik, Amar Ali
Publikováno v:
Diabetes, Obesity and Metabolism. 24:34-41
AIMS To assess the efficacy and safety of iGlarLixi (the titratable fixed-ratio combination of insulin glargine 100 U/mL [iGlar] plus lixisenatide [Lixi]), in adults with type 2 diabetes (T2D) with glycated haemoglobin (HbA1c) levels ≥8% (≥64 mmo
Autor:
Medha Munshi, Robert Ritzel, Irene Hramiak, Gagik Galstyan, Elisabeth Souhami, Terry Dex, Lydie Melas-Melt, Julio Rosenstock
Publikováno v:
Metabolism. 142:155429
Autor:
Elisabeth Souhami, Vanita R. Aroda, Stefano Del Prato, Lawrence Blonde, Juan P. Frias, Chen Ji, Julio Rosenstock, Elisabeth Niemoeller
Publikováno v:
Diabetes, Obesity and Metabolism. 23:1331-1341
AIM In people with type 2 diabetes (T2D) requiring intensification beyond glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and oral antihyperglycaemic drugs (OADs), switching to iGlarLixi was shown to be efficacious and well-tolerated in the Lix
Autor:
null Rory J. McCrimmon, null Philip Home, null Alice Cheng, null Francesco Giorgino, null Vivian Fonseca, null Elisabeth Souhami, null Agustina Alvarez, null Pascaline Picard, null Julio Rosenstock
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c8d7d6a2154345c1c43a3017ae0405b
https://doi.org/10.1111/dom.14825/v3/response1
https://doi.org/10.1111/dom.14825/v3/response1
Autor:
Xiaoyong, Yuan, Xiaohui, Guo, Junqing, Zhang, Xiaolin, Dong, Yibing, Lu, Wuyan, Pang, Shenghong, Gu, Elisabeth, Niemoeller, Lin, Ping, Gaowei, Nian, Elisabeth, Souhami
Publikováno v:
Diabetes, obesitymetabolismREFERENCES. 24(11)
To evaluate the efficacy and safety of iGlarLixi compared with iGlar in Chinese adults with type 2 diabetes advancing therapy from basal insulin ± oral antihyperglycaemic drugs.LixiLan-L-CN (NCT03798080) was a 30-week randomized, active-controlled,